Exenatide curbs glucose, weight in patients with type 2 diabetes

06/29/2011 | Medscape (free registration)

Taking injected extended-release once-weekly exenatide for 84 weeks improved the glycemic control, weight and hypoglycemia risk in patients with type 2 diabetes, according to a study presented at the annual meeting of the American Diabetes Association. Exenatide-treated patients had 1.2% reduction in hemoglobin A1c levels and lost an average of 4.5 pounds, experts said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX